2013
Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
Wang C, Yi T, Qin L, Maldonado RA, von Andrian UH, Kulkarni S, Tellides G, Pober JS. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. Journal Of Clinical Investigation 2013, 123: 1677-1693. PMID: 23478407, PMCID: PMC3613923, DOI: 10.1172/jci66204.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAnimalsArteriesB7-H1 AntigenCD4-Positive T-LymphocytesCell ProliferationCells, CulturedCoculture TechniquesFemaleGene ExpressionGene Knockdown TechniquesHuman Umbilical Vein Endothelial CellsHumansImmunosuppression TherapyInterleukin-6Lymphocyte ActivationMiceMice, SCIDProgrammed Cell Death 1 Ligand 2 ProteinRegulatory-Associated Protein of mTORRNA, Small InterferingSirolimusT-Lymphocytes, RegulatoryTOR Serine-Threonine KinasesTranscriptional ActivationTransplantation, HomologousConceptsEffect of rapamycinT cellsEndothelial cellsAllograft rejectionHuman endothelial cellsPD-L1PD-L2Allogeneic regulatory T cellsHuman-mouse chimeric modelInhibitory molecule PD-L1Inflammatory cytokines IL-6Alloantigen-specific mannerAllograft endothelial cellsHuman arterial allograftsImmune-mediated rejectionGraft endothelial cellsEffector T cellsRegulatory T cellsMemory T cellsT cell responsesAntigen-presenting cellsCytokines IL-6Mock-treated cellsAllogeneic CD4Effector cytokines
2011
Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells
Fogal B, Yi T, Wang C, Rao DA, Lebastchi A, Kulkarni S, Tellides G, Pober JS. Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells. The Journal Of Immunology 2011, 187: 6268-6280. PMID: 22084439, PMCID: PMC3237826, DOI: 10.4049/jimmunol.1003774.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsCell DifferentiationCells, CulturedChemotaxis, LeukocyteCoculture TechniquesCoronary VesselsDisease Models, AnimalEndothelium, VascularFemaleGraft RejectionHuman Umbilical Vein Endothelial CellsHumansInterleukin-6MiceMice, SCIDMyocytes, Smooth MuscleNeutralization TestsNK Cell Lectin-Like Receptor Subfamily BT-Lymphocytes, RegulatoryConceptsRegulatory T cellsT cell infiltrationMemory T cellsT cell proliferationT cellsIL-6Allograft rejectionCell infiltrationIntimal expansionEffector memory T cellsHuman coronary artery segmentsEndothelial cellsEnhanced T cell proliferationHuman allograft rejectionT-cell infiltratesExpression of Foxp3Coronary artery segmentsCell proliferationMHC class IIIL-6 transcriptsT cell activationImmunodeficient mouse hostsHuman IL-6Allograft vesselsPerioperative injury
2000
PROGRAMMED CELL DEATH SIGNALING VIA CELL-SURFACE EXPRESSION OF A SINGLE-CHAIN ANTIBODY TRANSGENE
Kulkarni S, Holman P, Kopelan A, van Seventer G, van Seventer J, Kranz D, Woodle E. PROGRAMMED CELL DEATH SIGNALING VIA CELL-SURFACE EXPRESSION OF A SINGLE-CHAIN ANTIBODY TRANSGENE. Transplantation 2000, 69: 1209-1217. PMID: 10762228, DOI: 10.1097/00007890-200003270-00028.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnnexin A5Antibodies, Anti-IdiotypicAntibodies, MonoclonalAntibody SpecificityApoptosisBinding Sites, AntibodyCHO CellsCoculture TechniquesCricetinaeFlow CytometryGene ExpressionHistocompatibility Antigens Class IHumansImmunoglobulin Variable RegionLymphoid TissueMembrane ProteinsPhosphatidylinositolsTransfectionTransgenesTumor Cells, CulturedConceptsPeripheral blood mononuclear cellsBlood mononuclear cellsClass I MHCMononuclear cellsI MHCMembrane expressionTumor cellsImmune modulatory signalsTypical histologic featuresHuman lymphoid tumor cellsHuman class I MHCPotential clinical utilityLymphoid tumor cellsWhole antibody moleculesV-fluorescein isothiocyanateHistologic featuresMonomorphic determinantsHLA-A2Responder cellsCell surface expressionClinical utilityTherapeutic strategiesSingle-chain variable antibodyMonoclonal antibodiesChinese hamster ovary cells